Genentech Seeks Higher Premium To Accept Acquisition By Roche
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at http://invivoblog.blogspot.com/.
You may also be interested in...
It's almost a certainty that five years from now gurus at top-notch B-schools will include the Roche/Genentech saga as a critical case-study in how-or how not-to acquire a partner. They will laud--or criticize--Severin Schwan, Roche's new CEO, for his chutzpah, pending the outcome of the ensuing weeks.
Roche's effort to clinch a buy-out of Genentech has moved to a new, critical stage of negotiations. But just how much can Roche afford to pay for the top-of-the-line biotech, which comes with A-list scientific talent, an extensive pipeline heavily weighted in the lucrative arena of oncology, and a price tag to match?
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.